Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey
Leading company profiles reveal details of key generics market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons to Buy
What was the size of the Turkey generics market by value in 2016?
What will be the size of the Turkey generics market in 2021?
What factors are affecting the strength of competition in the Turkey generics market?
How has the market performed over the last five years?
How large is Turkey's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Turkish generics market is expected to generate total revenues of $1.8bn in 2016, representing a compound annual growth rate (CAGR) of 6.2% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 0.1% between 2012 and 2016, to reach a total of 51.4% of total pharma volume in 2016.
In 2012, the Turkish government decided to provide free access to healthcare services for those earning less than roughly $150 per month, whilst those earning more paid a social security premium.
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
Sandoz International GmbH
Related MarketLine research
Figure 1: Turkey generics market value: $ billion, 2012-16(e)
Figure 2: Turkey generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Turkey generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Turkey generics market value forecast: $ billion, 2016-21
Figure 5: Turkey generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Turkey, 2016
Figure 7: Drivers of buyer power in the generics market in Turkey, 2016
Figure 8: Drivers of supplier power in the generics market in Turkey, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2016
Figure 12: DEVA Holding: revenues & profitability
Figure 13: DEVA Holding: assets & liabilities
Table 1: Turkey generics market value: $ billion, 2012-16(e)
Table 2: Turkey generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Turkey generics market geography segmentation: $ billion, 2016(e)
Table 4: Turkey generics market value forecast: $ billion, 2016-21
Table 5: Turkey generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
Table 7: DEVA Holding: key facts
Table 8: DEVA Holding: key financials ($)
Table 9: DEVA Holding: key financials (TL)
Table 10: DEVA Holding: key financial ratios
Table 11: Nobel Pharmaceuticals: key facts
Table 12: Sandoz International GmbH: key facts
Table 13: Turkey size of population (million), 2012-16
Table 14: Turkey gdp (constant 2005 prices, $ billion), 2012-16
Table 15: Turkey gdp (current prices, $ billion), 2012-16
Table 16: Turkey inflation, 2012-16
Table 17: Turkey consumer price index (absolute), 2012-16
Table 18: Turkey exchange rate, 2012-16
Single User License:
Corporate User License:
Abdi Ibrahim Ilac Sanayi ve Ticaret AS, DEVA Holding, Nobel Pharmaceuticals, Sandoz International GmbH
Generics, MarketLine, Turkey
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"